Sort
48,018 grants matching “immunotherapy”
The role of IL-27 in sustaining the exhausted CD8 T cell response to persistent infection and cancer.
$557,334John Ross Teijaro · Scripps Research Institute, The · R01 · FY2025 · AI
Nortriptyline-mediated attenuation of alpha-synuclein pathology in Parkinson's disease
$557,329Timothy J. Collier · Michigan State University · R01 · FY2017 · NS
Targeting Focal Adhesion Kinase to Improve RT-inducted Tumor Immunity
$557,274David G Denardo · Washington University · R01 · FY2022 · CA
Temporal analysis of the GBM tumor microenvironment during myeloid cell activating therapy
$557,266Ralph Weissleder · Massachusetts General Hospital · R01 · FY2024 · CA
T-cell intrinsic mechanisms of resistance to PD-1 checkpoint blockade
$557,231Michelle Krogsgaard · New York University School Of Medicine · R01 · FY2023 · CA
Bioinformatic Tools for Interpretation of Glycan Array Data
$557,113Jian Zhang · Z Biotech, Llc · R44 · FY2021 · GM
CD8 T cell-dependent pathways leading to immunopathology in cutaneous leishmaniasis
$557,097Phillip A. Scott · University Of Pennsylvania · R01 · FY2021 · AI
Improving CAR-T efficacy against solid tumors by expanding lymph node reservoirs of âstem-likeâ CAR-T cells
$557,041Shivani Srivastava · Fred Hutchinson Cancer Center · R37 · FY2024 · CA
Biomarker guided combinations for treating high-risk bladder cancer
$557,016Vinata B Lokeshwar · Augusta University · R01 · FY2023 · CA
Linking Synucleinopathy and Dysfunction of Olfactory Pathways
$557,016Patrik Brundin · Van Andel Research Institute · R01 · FY2019 · DC
Biomarker guided combinations for treating high-risk bladder cancer
$557,016Vinata B Lokeshwar · Augusta University · R01 · FY2025 · CA
Delineating Functional Immunity via Image-Guided PET
$556,992Nerissa Therese Viola · Wayne State University · R37 · FY2020 · CA
Evaluation of novel treatments in biochemically recurrent prostate
$556,986Ravi Madan · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
Targeting the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer with a Neoadjuvant Platform Clinical Trial
$556,932Lei Zheng · Johns Hopkins University · R01 · FY2022 · CA
Targeting B7-H3 in ovarian cancer
$556,817Gianpietro Dotti · Univ Of North Carolina Chapel Hill · R01 · FY2024 · CA
3D Models of Immunotherapy
$556,812David J Mooney · Harvard University · U01 · FY2020 · CA
Recombinant Interleukin-33 Immunotherapy for Pancreatic Cancer
$556,764Vinod P Balachandran · Sloan-Kettering Inst Can Research · P50 · FY2024 · CA
In vivo targeting of T cells to Enable an HIV Cure
$556,722Michael R Betts · University Of Pennsylvania · P01 · FY2025 · AI
Epigenetic Programming of T Cells for Enhanced Cellular Immunotherapy
$556,711Charles A Gersbach · Duke University · R01 · FY2024 · CA
National Gnotobiotic Resource Center
$556,690Ryan Balfour Sartor · Univ Of North Carolina Chapel Hill · P40 · FY2025 · OD
National Gnotobiotic Resource Center
$556,690Ryan Balfour Sartor · Univ Of North Carolina Chapel Hill · P40 · FY2024 · OD
Immunotherapy of low grade lymphoid malignancies
$556,675Adrian U Wiestner · National Heart, Lung, And Blood Institute · ZIA · FY2011 · HL
Determining how a Werner helicase (WRN) tumor suppressor complex regulates the human papillomavirus 16 life cycle
$556,659Iain Morgan · Virginia Commonwealth University · R01 · FY2025 · DE
Determining how a Werner helicase (WRN) tumor suppressor complex regulates the human papillomavirus 16 life cycle
$556,659Iain Morgan · Virginia Commonwealth University · R01 · FY2023 · DE
A Novel Anti-HER2/neu IgE for Breast Cancer Therapy
$556,615Manuel L Penichet · University Of California Los Angeles · R01 · FY2016 · CA